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Current Comments are a rapid outlet for scientific
opinions on a topic of general interest.
Recent studies have raised the intriguing possibility that losartan, the proto-
typical angiotensin II (AngII) receptor type 1 (AT1r) blocker (ARB), should be
used as a prophylactic drug akin to aspirin and statins. Other reports however
have questioned whether losartan is the real thing or is this a case of unbridled
enthusiasm fueling yet another bubble. While only time will tell, it is worth
reviewing the pros and cons regarding losartan’s broad therapeutic potential.
Since FDA approval in 1995, ARBs have been widely used to treat hyperten-
sion, cardiac hypertrophy and renal disease owing to their selective antagon-
ism of AngII-induced arterial muscle contraction, sympathetic pressor
mechanisms and aldosterone release [1]. Losartan was also shown to reduce
AT1r-induced TGFb activity in a mouse model of human cardiomyopathy
[2]. This last observation prompted investigators to test losartan in several
experimental models of tissue fibrosis, as TGFb is a potent determinant of
extracellular matrix (ECM) deposition and remodeling. The studies even-
tually converged on the discovery that losartan also can mitigate thoracic aortic
aneurysm (TAA) in Marfan syndrome (MFS), a common connective tissue
disease associated with mutations in the ECM protein fibrillin-1 [3]. This
seminal finding was welcomed by the medical community with understand-
able enthusiasm because it represented the first pharmacological treatment of
a condition whose treatment options were thought to be restricted to gene or
stem cell therapy.
Management of TAA progression in MFS currently relies on agents that
lower blood pressure to delay aortic dilation and on elective aortic root
replacement to prevent dissection and rupture. Aside from imparting
structural properties to tissues, fibrillin-1 regulates cell performance by
modulating extracellular bioavailability of latent TGFb complexes. Con-
sistent with the latter function, affected tissues from MFS patients and MFS
mice display promiscuous TGFb signaling, conceivably as the result of
improper regulation of TGFb bioavailability. Thus the beneficial impact of
losartan treatment on vessel dilation and tissue degeneration may reflect
respectively the drug’s anti-hypertensive and anti-TGFb signaling proper-
ties, which are both highly desirable outcomes in MFS patients. Not only did
losartan normalize aortic dilation and aortic wall architecture in MFS mice
(Fbn1C1039G/+ mice), but also a retrospective study of a small cohort of
severely affected MFS children revealed an appreciable benefit of using
ARBs to slow aortic root growth [3,4]. Additionally, losartan was reported to
improve skeletal muscle abnormalities of MFS mice and mice with either
Duchene muscular dystrophy (DMD) or age-related sarcopenia [5,6].
Furthermore the finding that losartan significantly reduces tumor growth
of AT1r over-expressing ERBB2-negative breast cancer xenografts implied
potential applications in cancer therapy [7]. The finding that improper
TGFb signaling is central to several pathological conditions therefore
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cal benefits beyond those originally envisioned, which
presumably reflect the multiple biological functions of
AT1r signaling [1,8]. However there are data advocating
an alternative view.
In contrast to full TAA rescue in Fbn1C1039G/+ mice,
losartan treatment only delays aortic dissection and rup-
ture in Fbn1mgR/mgR mice, which have a more substantial
fibrillin-1 abnormality and are more seriously affected
than Fbn1C1039G/+ mice (BT Baxter, personal communi-
cation). Losartan’s ability to blunt maladaptive aortic
tissue remodeling in MFS mice therefore appears to be
inversely proportional to the severity of the ECM defect,
which determines the extent of both tissue impairment
and TGFb dysregulation. It follows that different MFS
patients may respond differently to ARB treatment
depending on the nature of the FBN1 mutation and
genetic modifiers of ECM composition and TGFb and/
or AT1r activity. Additional studies have questioned the
broad applicability of losartan and other ARBs. First, the
original finding that TGFb antagonism improves
multiple manifestations in MFS mice was later counter-
balanced by losartan’s inability to normalize skeletal
abnormalities in these mutant mice [3,5,9]. Second, Bish
et al. [10] recently showed that losartan treatment of
DMD mice improves cardiomyopathy but not skeletal
muscle degeneration, as previously reported [5]. With
respect to losartan and cancer therapy, decreasing TGFb
signaling might in principle ameliorate the fibrosis associ-
ated with some tumors but might also promote growth of
early neoplasms, as TGFb is a potent tumor suppressor.
In spite of controversial findings, the above studies have
brought us closer to developing therapeutic strategies for
MFS that are based on experimental evidence and
mechanistic insights. Irrespective of being either a prox-
imal or distal effector of TAA progression, TGFb has
proven to be a viable biological target in a genetic disease
with few other therapeutic options. This in turn provides
the justification and means to search for highly specific
small molecule inhibitors that will circumvent potential
problems of losartan treatment, such as optimal dosage,
genetic variability in drug response, long-term side
effects etc. Even if losartan is not the anticipated panacea
for MFS and other diseases, there is still significant meritCurrent Opinion in Pharmacology 2012, 12:223–224 in using AT1r antagonism to dissect pathogenic mech-
anisms and identify more suitable biological targets. Last
but not least, the studies of MFS pathogenesis have
underscored the physiological importance of an under-
studied research topic, namely ECM-mediated control of
growth factor bioavailability. It seems therefore reason-
able to conclude that perhaps we should embrace rather
than repudiate controversial and paradoxical findings
for they are the dialectic engine that propels scientific
progress.
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